title: [Drugs stimulating insulin release. Importance of their use for improving glycemia, safety and quality of life in diabetes mellitus type 2].
abstract: Etiopathogenesis of diabetes mellitus is bipolar. On one hand there occurs impairment in beta-cell function caused by genetic factors or abnormal development during fetal period. On the other hand defects of peripheral insulin action are also of significant importance. The bipolarity is also expressed by changing relationship between genetic and environmental factors. Insulin release is connected with closing ATP-dependent kalium channel, a structure closely connected with sulfonylurea receptors. Several receptors may be distinguished: SUR1 in Langerhans isles and SUR2 in heart (SUR2A) and vessel smoot muscles (SUR2B). In the treatment of insulin release disorders sulfonylureas are still of significant importance though repaglinid and phenyloalanine derivates also have some clinical importance. Within sulfonylurea derivates there have been developed some preparations of slow drug release (Glibenese GITS, Diaprel MR). One daily dose of Glibenese GITS and lower tendency to hypoglycaemia favour acceptation of the therapy by the patients what is also important for their quality of life. Quality of life is now regarded as important as obtaining good indices of diabetes control.
authors.affiliation: Katedra i Klinika Chorób Metabolicznych Uniwersytetu Jagiellońskiego w Krakowie.
authors.forename: J
authors.initials: J
authors.lastname: Sieradzki
mesh_terms: D018528:ATP-Binding Cassette Transporters; D015220:Calcium Channels / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D015221:Potassium Channels / Q000187:drug effects / Q000378:metabolism; D024661:Potassium Channels, Inwardly Rectifying; D011788:Quality of Life; D011955:Receptors, Drug / Q000187:drug effects / Q000378:metabolism; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D064233:Sulfonylurea Receptors
chemical_list: C577507:ABCC8 protein, human; C577510:ABCC9 protein, human; D018528:ATP-Binding Cassette Transporters; D015220:Calcium Channels; D007004:Hypoglycemic Agents; D007328:Insulin; D015221:Potassium Channels; D024661:Potassium Channels, Inwardly Rectifying; D011955:Receptors, Drug; D013453:Sulfonylurea Compounds; D064233:Sulfonylurea Receptors